Back to top
more

VERADIGM INC (MDRX)

(Delayed Data from OTC)

$7.96 USD

7.96
249,847

+0.01 (0.13%)

Updated Apr 26, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Technology Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merit Medical's (MMSI) Product Included in FDA's Program

by Zacks Equity Research

Receipt of the Breakthrough Device Designation for Merit Medical's (MMSI) Embosphere Microspheres is expected to improve patient outcome.

AmerisourceBergen (ABC) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.

Riya Anand headshot

4 Stocks in Spotlight With AI Making Inroads in MedTech

by Riya Anand

MedTech stocks like Medtronic (MDT), Stryker (SYK), Allscripts Healthcare Solutions (MDRX) and Syneos Health (SYNH) are evolving rapidly in the field of AI-driven technologies.

Dexcom's (DXCM) CGM Gets FDA's Breakthrough Device Designation

by Zacks Equity Research

Dexcom's (DXCM) CGM's use in the hospital setting is likely to be more effective in glycemic management and improved patient outcomes.

Henry Schein (HSIC) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Henry Schein's (HSIC) favorable dental business trends.

Veeva (VEEV) Beats on Q4 Earnings, Narrows '23 Revenue View

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal Q4 results reflect impressive performances by both of its segments.

Masimo's (MASI) SedLine Receives FDA's Pediatric Indication

by Zacks Equity Research

The latest FDA clearance for Masimo's (MASI) SedLine is likely to improve brain function monitoring in pediatric patients.

Inogen (INGN) Stock Surges 16.5% Despite Q4 Earnings Miss

by Zacks Equity Research

Inogen's (INGN) fourth-quarter results benefit from higher revenues across the majority of its geographical segments.

OPKO Health's (OPK) Q4 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research

OPKO Health's (OPK) fourth-quarter results benefit from continued strength in its Pharmaceuticals segment.

Merit Medical's (MMSI) Q4 Earnings, Revenues Top Estimates

by Zacks Equity Research

Merit Medical (MMSI), in the fourth quarter, benefits from revenue growth in both its segments, and from majority of the product categories within its Cardiovascular unit.

Debanjana Dey headshot

Allscripts' (MDRX) Q4 Earnings Beat Estimates, Margins Up

by Debanjana Dey

Allscripts' (MDRX) robust Q4 results demonstrate strength in both segments.

AllScripts Healthcare (MDRX) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

AllScripts (MDRX) delivered earnings and revenue surprises of 154.84% and 0.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.

DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong segmental performance.

Fulgent Genetics (FLGT) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

In terms of COVID-19 NGS revenues, Fulgent Genetics (FLGT) is expected to have witnessed a rise in testing volume on increased demand through the Q4 months.

NextGen (NXGN)-Verato Tie Up to Improve Patient Insights

by Zacks Equity Research

NextGen (NXGN) expects to deliver better insights into patient health history with its latest collaboration with Verato.

Medtronic (MDT) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Medtronic (MDT) might report low procedure volumes in the fiscal third quarter in markets where its technologies are used in more deferrable procedures.

Zacks Industry Outlook Highlights: Change Healthcare, Allscripts Healthcare Solutions and Computer Programs and Systems, Inc

by Zacks Equity Research

Change Healthcare, Allscripts Healthcare Solutions and Computer Programs and Systems, Inc. are highlighted in this Industry Outlook article.

AllScripts Healthcare (MDRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

AllScripts (MDRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Veeva Systems (VEEV) Vault CDMS to Aid Idorsia's Clinical Trials

by Zacks Equity Research

Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.

Urmimala Biswas headshot

3 Medical Info Systems Stocks Braving Industry-wide Headwinds

by Urmimala Biswas

Medical Info Systems stocks like Change Healthcare (CHNG), Allscripts Healthcare Solutions (MDRX) and Computer Programs and Systems, Inc. (CPSI) are expected to gain despite pandemic-led disruptions.

AMN Healthcare (AMN) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

AMN Healthcare's (AMN) fourth-quarter results are likely to reflect solid demand in some of the areas of its business.

Is iRadimed (IRMD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how iRadimed (IRMD) and AllScripts Healthcare (MDRX) have performed compared to their sector so far this year.

Quidel (QDEL) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Quidel's (QDEL) fourth-quarter results are likely to reflect continued strength across its SARS-related products.

Bruker (BRKR) Q4 Earnings Meet Estimates, Revenues Surpass

by Zacks Equity Research

Robust performance by the BSI and BEST segments drove Bruker's (BRKR) fourth-quarter top line.